Why your GLP‑1 ads keep getting rejected

Almost every clinic we talk to has a rejection story. An ad set that ran fine for two months and then stopped. An account restricted overnight. A campaign stuck in review long enough that the promotion it supported came and went.

The instinct is to treat it as bad luck, resubmit, and hope. Rejections are rarely random, though. They usually trace back to a small number of causes, and most of them are fixable before you ever hit publish.

The landscape shifted, and a lot of copy did not

The biggest single factor is that marketing which was tolerated a few years ago is now a liability. Mass-market advertising of compounded semaglutide and tirzepatide as a cheap equivalent to branded product sits squarely in the category platforms and regulators have tightened.

If your landing page still sells compounded product like a commodity — price first, equivalence implied, oversight barely mentioned — you are advertising into a risk surface. State attorneys general have taken an interest. Platforms have adjusted their review models accordingly.

What replaces it is not weaker marketing. It is marketing that reflects licensed distribution pathways and documented prescriber supervision, and that does not promise every patient the same outcome.

Four things that trigger a rejection

Equivalence claims. Copy framing a compounded product as “just like” Wegovy or Zepbound. This is the fastest route to a rejection, and it is frequently buried in a subheading nobody reviewed.

Before-and-after framing. Dramatic transformation imagery and specific pound-count promises read as personal health claims. Platforms are explicit about this and enforce it unevenly enough that people assume they got away with it — until they do not.

A landing page that contradicts the ad. This is the one clinics miss most. Creative that clears review still dies if the destination page makes claims the ad avoided. Review looks at both. Build them as one compliant system, not an approved ad pointing at whatever the site already said.

Targeting that implies a health condition. Audience setups that suggest you know something personal about the user run into a separate set of restrictions from the creative rules.

Clearance is a design goal, not a gamble

The clinics that stop having rejection problems are the ones that treat compliance as an input to the creative brief rather than a review step at the end.

In practice that means writing the eligibility language before the hook, deciding what the page can claim before designing it, and keeping a prescription-advertising checklist your team can reuse — so the next campaign starts from a known-good baseline instead of somebody’s memory of what happened last time.

Nobody can guarantee a platform decision. You can design for clearance, and clearance is the single biggest reason clinic campaigns stall or scale.

If you are already flagged

A restricted account is a different problem from a rejected ad, and resubmitting the same creative usually makes it worse. The sequence that works is an audit of the rejection points, a compliant rebuild of the copy and landing page, and a clean relaunch — not an appeal followed by hope.

We do this as a fixed-scope engagement: see Ad Account Recovery. If you want the broader picture of what changed and what it means for your ads, we wrote that up on the GLP-1 marketing compliance page.

And if the ads are clearing but the leads are not booking, the problem has moved downstream — that is usually a conversion and follow-up issue, not a policy one.